NCT01179217 2020-08-19A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemiaEmmaus Medical, Inc.Phase 3 Completed230 enrolled 19 charts 1 FDA
NCT01895361 2020-01-31SUSTAINReprixys Pharmaceutical CorporationPhase 2 Completed198 enrolled 18 charts 1 FDA